SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1
Newly emerged SARS-CoV-2 is the cause of an ongoing global pandemic leading to severe respiratory disease in humans. SARS-CoV-2 targets epithelial cells in the respiratory tract and lungs, which can lead to amplified chloride secretion and increased leak across epithelial barriers, contributing to severe pneumonia and consolidation of the lungs as seen in many COVID-19 patients. There is an urgent need for a better understanding of the molecular aspects that contribute to SARS-CoV-2 induced pathogenesis and for the development of approaches to mitigate these damaging pathologies. The multifunctional SARS-CoV-2 Envelope (E) protein contributes to virus assembly/egress, and as a membrane protein, also possesses viroporin channel properties that may contribute to epithelial barrier damage, pathogenesis, and disease severity. The extreme C-terminal (ECT) sequence of E also contains a putative PDZ-domain binding motif (PBM), similar to that identified in the E protein of SARS-CoV-1. Here, we screened an array of GST-PDZ domain fusion proteins using either a biotin-labeled WT or mutant ECT peptide from the SARS-CoV-2 E protein. Notably, we identified a singular specific interaction between the WT E peptide and the second PDZ domain of human Zona Occludens-1 (ZO1), one of the key regulators of TJ formation/integrity in all epithelial tissues. We used homogenous time resolve fluorescence (HTRF) as a second complementary approach to further validate this novel modular E-ZO1 interaction. We postulate that SARS-CoV-2 E interacts with ZO1 in infected epithelial cells, and this interaction may contribute, in part, to tight junction damage and epithelial barrier compromise in these cell layers leading to enhanced virus spread and severe respiratory dysfunction that leads to morbidity. Prophylactic/therapeutic intervention targeting this virus-host interaction may effectively reduce airway barrier damage and mitigate virus spread.
| Errataetall: |
UpdateIn: PLoS One. 2021 Jun 9;16(6):e0251955. - PMID 34106957 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 23. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shepley-McTaggart, Ariel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral therapeutic |
|---|
| Anmerkungen: |
Date Revised 19.10.2023 published: Electronic UpdateIn: PLoS One. 2021 Jun 9;16(6):e0251955. - PMID 34106957 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.12.22.422708 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319621774 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319621774 | ||
| 003 | DE-627 | ||
| 005 | 20231225171836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.22.422708 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319621774 | ||
| 035 | |a (NLM)33398268 | ||
| 035 | |a (PII)2020.12.22.422708 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shepley-McTaggart, Ariel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: PLoS One. 2021 Jun 9;16(6):e0251955. - PMID 34106957 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Newly emerged SARS-CoV-2 is the cause of an ongoing global pandemic leading to severe respiratory disease in humans. SARS-CoV-2 targets epithelial cells in the respiratory tract and lungs, which can lead to amplified chloride secretion and increased leak across epithelial barriers, contributing to severe pneumonia and consolidation of the lungs as seen in many COVID-19 patients. There is an urgent need for a better understanding of the molecular aspects that contribute to SARS-CoV-2 induced pathogenesis and for the development of approaches to mitigate these damaging pathologies. The multifunctional SARS-CoV-2 Envelope (E) protein contributes to virus assembly/egress, and as a membrane protein, also possesses viroporin channel properties that may contribute to epithelial barrier damage, pathogenesis, and disease severity. The extreme C-terminal (ECT) sequence of E also contains a putative PDZ-domain binding motif (PBM), similar to that identified in the E protein of SARS-CoV-1. Here, we screened an array of GST-PDZ domain fusion proteins using either a biotin-labeled WT or mutant ECT peptide from the SARS-CoV-2 E protein. Notably, we identified a singular specific interaction between the WT E peptide and the second PDZ domain of human Zona Occludens-1 (ZO1), one of the key regulators of TJ formation/integrity in all epithelial tissues. We used homogenous time resolve fluorescence (HTRF) as a second complementary approach to further validate this novel modular E-ZO1 interaction. We postulate that SARS-CoV-2 E interacts with ZO1 in infected epithelial cells, and this interaction may contribute, in part, to tight junction damage and epithelial barrier compromise in these cell layers leading to enhanced virus spread and severe respiratory dysfunction that leads to morbidity. Prophylactic/therapeutic intervention targeting this virus-host interaction may effectively reduce airway barrier damage and mitigate virus spread | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Envelope (E) protein | |
| 650 | 4 | |a PDZ binding motif (PBM) | |
| 650 | 4 | |a PDZ-domain | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a ZO-1 | |
| 650 | 4 | |a antiviral therapeutic | |
| 650 | 4 | |a tight junction | |
| 650 | 4 | |a virus-host interaction | |
| 700 | 1 | |a Sagum, Cari A |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Isabela |e verfasserin |4 aut | |
| 700 | 1 | |a Rybakovsky, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a DiGuilio, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Bedford, Mark T |e verfasserin |4 aut | |
| 700 | 1 | |a Cassel, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Sudol, Marius |e verfasserin |4 aut | |
| 700 | 1 | |a Mullin, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Harty, Ronald N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 23. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:23 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.22.422708 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 23 |c 12 | ||